Choose physicianled care that protects your health, your results, and your peace of mind
Several clinical studies have shown a positive effect of MeD on the reduction of the risk of developing chronic metabolic diseases such as diabetes mellitus, cardiovascular diseases, arterial hypertension, but also cancer, neurodegenerative diseases and osteoporosis
Peptide therapy is not for everyone, which is exactly why every plan starts with a provider review
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to diet and physical activity
We saw a notable decline in the use of traditional, lower-cost diabetes therapies such as metformin and insulin and a significant rise in the adoption of newer, high-cost therapies such as GLP-1s